Introduction {#s0001}
============

4-Nerolidylcatechol (4-NRC) ([Figure 1](#F0001){ref-type="fig"}) is the main secondary metabolite found in the Brazilian plant *Pothomorphe umbellata* (L.) Miq. (Piperaceae) (Cunha et al. [@CIT0014]). Several studies have demonstrated the *in vitro* and *in vivo* antioxidant activity of 4-NRC using different experimental models (Desmarchelier et al. [@CIT0015]; Ropke et al. [@CIT0043], [@CIT0044], [@CIT0045]; Barros et al. [@CIT0006]). In these studies, 4-NRC has showed inhibitory activity against MMP-2 and MMP-9 metalloproteinases, which suggests that this compound has an antioxidant mechanism, which attenuates solar UVB light-induced skin carcinogenesis (Ropke et al. [@CIT0045]). Moreover, 4-NRC showed a protective effect against cyclophosphamide-induced genotoxicity (Valadares et al. [@CIT0054]). This compound and/or its semi-synthetic derivatives also presented *in vitro* antioxidant, antimicrobial, antimalarial and antitumor activities (Brohem et al. [@CIT0009]; Silva Pinto et al. [@CIT0048]; Bagatela et al. [@CIT0005]; Cunha et al. [@CIT0014]; Cortez et al. [@CIT0013]). In terms of anticancer properties, it has been shown that apoptosis is the main cell death type triggered by 4-NRC (Brohem et al. [@CIT0009], [@CIT0010]). However, the mechanisms by which it induces apoptosis in cancer cells are still unclear, especially in leukemic cells.

![Chemical structure of 4-nerolidylcatechol (4-NRC), the main secondary metabolite found in Brazilian plants such as *Pothomorphe umbellata*.](IPHB_A_1311351_F0001_B){#F0001}

In view of this, the K562 human leukemic cell line has been widely used as a model to evaluate the antineoplastic potential of new drugs and to investigate the pathways involved in the cell death. This cell line does not express p53 (Sen et al. [@CIT0047]), a protein involved in tumour proliferation inhibition (Vousden & Prives [@CIT0056]). In addition, it is derived from chronic myelogenous leukaemia, characterized by the presence of the Philadelphia (Ph) chromosome, which is formed by translocation between chromosomes 9 and 22 (Miller et al. [@CIT0032]). This genetic aberration produces the BCR-ABL tyrosinase kinase oncoprotein fusion, active in more than 90% of the patients and responsible for the overproduction of chronic myeloid leukemic (CML) cells (Huang et al. [@CIT0024]; Mota et al. [@CIT0034]). In addition, BCR-ABL-expression in K562 cells presents resistance to apoptosis induced by conventional chemotherapeutics and allows for the evaluation of several cellular and molecular events concurrently, which justifies the use of this valuable cellular model in drug discovery (Huang et al. [@CIT0024]; Mota et al. [@CIT0034]).

In this respect, mitochondrial alterations have been associated to CML cell drug resistance by mechanisms involving the intrinsic apoptotic pathway (Koptyra et al. [@CIT0026]; Tokarz & Blasiak [@CIT0053]). Apoptosis is the type of cell death with different pathways which is most studied. In most of these pathways, mitochondrial membrane permeabilization and/or caspase activation are considered central points of integration of the apoptotic cell death (Savitskaya & Onishchenko [@CIT0046]). As regards mitochondria, newly accumulated evidence supports the idea that cell cycle regulators, such as cyclin D1, are actively involved in mitochondrial regulation/homeostasis through the phosphorylation of their mitochondrial targets (Pestell [@CIT0038]; Alexandrou & Li [@CIT0003]). In this respect, new approaches in mitochondria-oriented anticancer therapy are suggested.

Based on the above, this study evaluated the antileukemic activity and apoptotic pathways involved in 4-NRC-induced cell death in p53-null K562 leukemic cells.

Materials and methods {#s0002}
=====================

Chemicals {#s0003}
---------

RPMI 1640 medium, fetal bovine serum, streptomycin, penicillin G, 3-\[4,5-dimethylthiazol-2-yl\]-2,5-diphenyl tetrazolium bromide (MTT), propidium iodide (PI), Giemsa dye, RNase type I, dichloro-dihydro-fluorescein diacetate (DCFH-DA), rhodamine 123, 5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazolylcarbo-cyanine iodide (JC-1), bovine serum albumin (BSA), phytohemagglutinin, ficoll-hypaque, N-acetyl-[l]{.smallcaps}-cysteine, protease inhibitor cocktail and bicinchoninic acid protein assay kit were purchased from Sigma-Aldrich (St. Louis, MO). Annexin V Apoptosis Detection Kit FITC was acquired from eBioscience^®^ (San Diego, CA), while a CaspaTag^TM^ Caspase-3/7, -8 and -9 *In Situ* Assay kit was obtained from Millipore^TM^ (Temecula, CA). The antibody against cyclin D1 (A-12) (sc-8396), cyclin D1 (H-295) rabbit polyclonal IgG (sc-753) and cytochrome c (6H2) (sc-13561) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) while BD cell-tak^TM^ adhesive and BD Cytofix/Cytoperm™ solution were acquired from BD Biosciences (San Jose, CA). NP-40 lysis buffer was purchased from Amresco (Solon, OH) and antibody against GAPDH and anti-rabbit IgG (Fc), AP conjugate were obtained from Promega (Madison, WI). MitoTracker^®^ Red CMXRos probe and Hoechst 33342 were purchased from Life Technologies (Carlsbad, CA) and Invitrogen (Grand Island, NY), respectively. Acetonitrile, methanol, ethanol, hexane and dichloromethyl were acquired from Merck (Darmstad, Germany), whereas Tween 20 was obtained from Vetec (Rio de Janeiro, RJ, Brazil).

Preparation of *P. umbellata* root extract {#s0004}
------------------------------------------

Plant material of *P. umbellata* was collected from the medicinal herb garden of the University of São Paulo (May--September, 2008), and a sample deposited in the Herbarium of the Institute of Biosciences of the University of São Paulo (Kato-0363). The roots were dried and ground to a powder and finally extracted by percolation, as recommended by method A of the Brazilian Pharmacopoeia, in a 3:1 solution of ethanol and water. The organic solvent was evaporated and the water layer extracted with chloroform. The recovered residue was filtered and quantified for 4-NRC content. The 4-NRC concentration found in the crude extract residue was 21.5% (w/w), as assayed by HPLC-UV detection (Rezende & Barros [@CIT0041]). Briefly, the crude extract 4-NRC assay was monitored at 282 nm and carried out using a water-acetonitrile-methanol solvent system 18:20:62 as the mobile phase and flow rate was maintained at 1.0 mL/min. HPLC analysis was carried out using a Varian^®^ Prostar HPLC model 210 (Walnut Creek, CA) equipped with a UV/VIS detector (Prostar, model 340), a Reodyne^®^ injector loop (20 μL) and a reverse-phase column Phenomenex^®^ Synergi Fusion 4 μ RP-80 A C18 (150 mm × 4.6 mm) (Torrance, CA), protected by a precolumn cartridge.

Obtaining 4-NRC {#s0005}
---------------

4-NRC (molecular weight: 318.4) was isolated from the crude *P. umbellata* extract, as described elsewhere (Gustafson et al. [@CIT0022]). Briefly, the ethanol:water extract was submitted to a Sephadex™ LH20 chromatography column (21 × 10 cm) and eluted with hexane: CHCl~2~:MeOH. The presence of 4-NRC in chromatographic fractions was detected by TLC, by comparing to a previously isolated authentic sample. The structure was confirmed by spectral analysis (^1 ^H, ^13 ^C NMR) in agreement with published data (Gustafson et al. [@CIT0022]). For the assays, 4-NRC was dissolved in ethanol to a concentration of 5.34 mM and stored at −20 °C.

Cell cultures {#s0006}
-------------

The human CML K562, immature T Jurkat and HL-60 cell lines, obtained from the Rio de Janeiro Cell Bank (Federal University of Rio de Janeiro, Rio de Janeiro, Brazil), were cultured in suspensions in RPMI 1640 medium supplemented with 10% foetal bovine serum (FBS), 100 U/mL of penicillin and 100 μg/mL of streptomycin in a humidified atmosphere at 37 °C in 5% CO~2~. Cells were seeded (1 × 10^5^ cells/mL) in 96-well microtiter plates and incubated with eight concentrations of 4-NRC (4.17--534.5 μM) for 24 h in an incubator (Thermo Scientific, USA) with humidified atmosphere at 37 °C in 5% CO~2~. Control cells were treated with complete medium only.

Lymphocyte culture {#s0007}
------------------

Lymphocytes were obtained according to the standard protocol described by Preston et al. ([@CIT0039]). In brief, a peripheral human blood sample, randomly and anonymously obtained as a residual product from a clinical laboratory, was diluted with an equal volume of RPMI 1640 medium, then layered over Ficoll-Hypaque density gradient separation solution (1.077 g/mL), and centrifuged at 2000 rpm for 20 min at room temperature (Rotina 38 R centrifuge system from Hettich, Baden-Württemberg, Germany). The mononuclear cell layer was removed, washed twice in RPMI 1640 medium and resuspended in RPMI 1640 medium supplemented with 10% FBS and antibiotics. Lymphocytes (1 × 10^6^ cells/mL) were cultured with phytohemagglutinin (10 μg/mL) in 96-well microtiter plates, in the presence and absence of 4-NRC (4.17--534.5 μM), for 24 h in 37 °C in 5% CO~2~ incubator.

Cytotoxicity assay {#s0008}
------------------

After treatment of each cell line and lymphocytes with 4-NRC, cytotoxicity was determined by 3-\[4,5-dimethylthiazol-2-yl\]-2,5-diphenyl tetrazolium bromide (MTT) reduction assay, adapted from Mosmann ([@CIT0033]). Briefly, the cells were seeded in a 96-well microtiter plates and treated with 4-NRC for 24 h. After that, 10 μL/well MTT (5 mg/mL) were added and the plates were incubated for 3 h at 37 °C. After the plates were centrifuged at 800 rpm for 10 min, the supernatant was removed and 200 μL/well of DMSO were added to solubilize the formazan formed. The absorbance was measured at 560 nm using a spectrophotometer. Each concentration of 4-NRC was tested in three independent experiments in six replicates. The data are expressed as % of the cell proliferation or viability of control cells (100%). For all subsequent assays, IC~50~ value (concentration that inhibited cell growth in 50% compared to untreated group) obtained in the MTT assay was used.

Morphological changes {#s0009}
---------------------

K562 cells, treated with 4-NRC (27 μM) for 24 h, were performed on cytospin preparations on microscope slides and stained with Giemsa dye (Fernandes et al. [@CIT0018]). After drying naturally, the morphological changes in the cells were observed under a light microscopy (AxioZeiss, Zeiss, Germany).

FITC annexin V/propidium iodide double staining and analysis {#s0010}
------------------------------------------------------------

The assay was performed using an Annexin V Apoptosis Detection Kit FITC (eBioscience^®^, San Diego, CA) in accordance with the manufacturer's instructions. Briefly, after treatment with 4-NRC (27 μM) for 24 h, K562 cells were harvested, washed twice with cold PBS and resuspended in binding buffer (0.1 M Hepes/NaOH, pH 7.4; 1.4 M NaCl and 25 mM CaCl~2~). The suspensions were transferred to 5 mL tubes and 5 μL FITC Annexin V and 5 μL of propidium iodide (PI) were added. The cells were incubated at room temperature for 15 min, after which 400 μL binding buffer were added and analysis was performed in a FACSCanto II flow cytometer (Becton Dickinson, CA) using the FACSDiva software. Simultaneously, cell groups were also pretreated with NAC antioxidant agent (2 mM), a ROS scavenger, for 1 h following treatment with 4-NRC to evaluate the involvement of ROS in apoptosis induction. Four cell populations were identified: necrotic cells in the upper-left quadrant (high PI and low FITC signals); early apoptotic cells in the lower-right quadrant (low PI and high FITC signals); late apoptotic cells in the upper-right quadrant; and viable cells in the lower-left quadrant (low PI and FITC signals).

Cell cycle and sub-G1 analysis {#s0011}
------------------------------

After treatment, K562 cells (1 × 10^6^ cells/mL) were harvested, washed with cold PBS and fixed with ice-cold 70% ethanol for at least 24 h. The cells were washed twice with PBS by centrifuging at 1500 rpm for 10 min. Cells were then treated with 4 μg/mL RNase type I for 1 h at 37 °C and resuspended in PBS. Cells were stained with 25 μg/mL of PI and analyzed in a flow cytometer (Ávila et al. [@CIT0004]).

Cyclin D1 expression analysis {#s0012}
-----------------------------

Flow cytometry and western blot analysis were performed for the detection of the expression level of cyclin D1 protein in K562 cells, based on the protocols described by Cortez et al. ([@CIT0013]) and Mota et al. ([@CIT0035]), respectively. After treatment, K562 cells (1 × 10^6^ cells/mL) were harvested by centrifugation, washed with cold PBS and resuspended with BD Cytofix/Cytoperm™ solution for 20 min at 4 °C. Cells were washed twice with cold PBS containing Tween 20 (0.01%) by centrifuging at 1500 rpm for 10 min. After that, 20 μL of antibody anti-cyclin D1 were added and cells were incubated in the dark at room temperature for 30 min. After washing in PBS/1% BSA, cells were resuspended in 400 μL PBS and analyzed in a flow cytometer.

For Western blot analysis, cell lysates were prepared with NP-40 lysis buffer (containing a protease inhibitor cocktail) for 30 min on ice. The cell debris were pelleted by centrifugation at 13,000 rpm and 4 °C for 10 min, and the supernatant was recovered. Protein content of the cell lysates was measured using bicinchoninic acid protein assay kit (Sigma-Aldrich); and 40 μg of protein were separated on a 10% SDS-polyacrylamide gel and electro-transferred to PVDF membranes. After blocking with 5% non-fat skim milk powder in BSA, the membranes were incubated with an antibody against cyclin D1 (1:200). The blots were washed three times with TBST and incubated with the secondary antibody tagged with alkaline phosphatase (1:500) for 1.5 h. After washing with TBST for 30 min, the cyclin D1 protein was detected using the chromogenic substrate BCIP/NBT. Equal protein loading in each lane was confirmed by probing with an anti-GAPDH antibody (1:1000). The bands were visualized and quantified by densitometry using the open-source ImageJ software (<https://imagej.nih.gov/ij/>). The assays were carried out by two independent experiments.

Evaluation of mitochondrial transmembrane potential (ΔΨm) {#s0013}
---------------------------------------------------------

The ΔΨm changes were detected using rhodamine 123, a dye sequestered by active mitochondria, and confirmed by JC-1 potentiometric probe that remains in cytoplasma as monomeric form in apoptotic cells, while in viable cells it forms mitochondrial aggregates. Both the assays were conducted in accordance with the manufacturer's instructions. Similar to that described previously, control and treated cells were incubated with rhodamine 123 (1 μg/mL) in PBS or JC-1 (2.5 μg/mL) in RPMI for 15 min. After that, the cells were washed and analyzed using flow cytometer.

Evaluation of mitochondrial activity {#s0014}
------------------------------------

Mitochondrial activity was measured by staining cells with MitoTracker Red, a fluorochrome that measures mitochondrial mass in a ΔΨm-dependent manner, in accordance with the manufacturer's instructions. After treatment, K562 cells (1 × 10^6^ cells/mL) were washed twice with PBS and incubated with MitoTracker^®^ Red CMXRos (10 nM) in PBS for 15 min at 37 °C in 5% CO~2~. The cells were washed twice, resuspended in 0.2 mL of PBS and analysis was performed in a flow cytometer.

Cytochrome c release analysis {#s0015}
-----------------------------

Cytochrome c release from mitochondria to cytoplasm was evaluated using a fluorescence microscope (DMI 4000 B Leica Microsystems, Bannockburn, IL) coupled to the software LAS-AF. The control and 4-NRC-treated cells (1 × 10^6^ cells/mL) were fixed with methanol and then seeded on BD cell-tak^TM^-coated coverslips. Cells were permeabilized and blocked with PBS solution containing BSA (1%, p/v) and Tween 20 (0.1%, v/v) in humidified chamber for 1 h, at room temperature. Then the cells were incubated with cytochrome c antibody for 1 h and nuclei were stained with Hoechst 33258. The cells were then washed three times with PBS and mounted, using an appropriate mounting medium (PBS with 90% glycerol, v/v).

Measurement of intracellular ROS {#s0016}
--------------------------------

Based on the protocol described by Ávila et al. ([@CIT0004]), intracellular ROS production was measured by using a fluorimetric probe, 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA), which can be hydrolyzed to 2,7-dichlorodihydrofluorescein (DCFH) by intracellular esterases when the cells take it up. DCFH is reactive with ROS to give a new highly fluorescent compound, 2,7-dichlorofluorescein (DCF), which can be detected by a flow cytometer. After treatment with 4-NRC, as described above, K562 cells (1 × 10^6^ cells/mL) were incubated with DCFH-DA (10 μM) at 37 °C in 5% CO~2~ for 1 h and analyzed in a flow cytometer.

Caspase activity {#s0017}
----------------

After incubation of K562 cells with 4-NRC (27 μM) for 24 h, the active caspases -3/7, -8 and -9 were assessed by a flow cytometer using the CaspaTag^TM^ Caspase *In Situ* Assay kit (Millipore, Temecula, CA) in accordance with the manufacturer's instructions. To evaluate the involvement of ROS in caspase activation, cell groups were also pretreated with NAC (2 mM) for 1 h following treatment with 4-NRC.

Statistical analysis {#s0018}
--------------------

The assays were performed as two or three independent experiments. The cytotoxicity results, expressed as the mean ± SD of six replicates, were transformed into percentages of the control, and IC~50~ values were obtained by non-linear regression. For flow cytometry analysis, 10,000 events were collected per sample of each assay with a FACSCanto II flow cytometer using the FACSDiva software version 6.0. The difference between control and 4-NRC-treated cells was evaluated by unpaired *t* test or one/two way analysis of variance (ANOVA) and Bonferroni test using GraphPad Prism version 5.01 software for Windows (San Diego, CA). Statistical significance was considered when *p* \< 0.05.

Results {#s0019}
=======

The cytotoxic effects of the eight concentrations of 4-NRC (4.1--534.5 μM) in K562, HL-60 and Jurkat cells by MTT assay are shown in [Figure 2(A)](#F0002){ref-type="fig"}. The proliferation of these leukemic cells was inhibited by 4-NRC, in a concentration dependent-manner. IC~50~ values obtained were 27.31 ± 5.6, 15.93 ± 1.9, and 15.70 ± 3.8 μM for K562, HL-60 and Jurkat cells, respectively. In addition, 4-NRC also showed cytotoxicity to normal lymphocytes from human peripheral blood (IC~50~ = 11.40 ± 0.42 μM) ([Figure 2(A)](#F0002){ref-type="fig"}).

![Cytotoxic effects of 4-NRC in lymphocytes and leukemic cells. (A) Lymphocytes and K562, HL-60 and Jurkat cells (1 × 10^6^ cells/mL) were treated with different concentrations of 4-NRC (4.17--534.5 μM) for 24 h and cell viability was determined by MTT assay. Results represent the mean ± SD of three independent experiments in six replicates. (B) Morphological changes promoted by 4-NRC in K562 cells: control cells (2 × 10^4^/mL) stained with Giemsa dye showed normal nucleus while cells treated with 4-NRC (27 μM) for 24 h showed apoptotic nucleus (indicated by arrow). Representative photomicrographs (400 × magnification) of two independent experiments.](IPHB_A_1311351_F0002_B){#F0002}

Since K562 cells show resistance to apoptosis induced by conventional chemotherapeutics, this cell line was chosen for subsequent assays to evaluate cell death pathways triggered by 4-NRC (IC~50~ = 27 μM). [Figure 2(B)](#F0002){ref-type="fig"} shows the morphological changes in K562 cells after treatment with 4-NRC for 24 h. As can be seen, the treated cells presented apoptotic characteristics when compared to untreated cells. These findings prompted us to investigate the mechanisms of the 4-NRC-induced apoptosis in K562 cells.

Cells undergoing apoptosis suffer changes in their phospholipid bilayer membrane which include phosphatidylserine (PS) externalization to the outer plasma membrane during early and late apoptotic events. [Figure 3(A,B)](#F0003){ref-type="fig"} shows the binding of annexin V (A)/propidium iodide (PI) in K562 cells after 4-NRC treatment. As expected, untreated cells showed mainly viable (A-/PI-) (91.0 ± 1.1%). By contrast, cells treated with 4-NRC showed a significant reduction in viability as the following shows: viable (61.2 ± 9.8%, A-/PI-) (*p* \< 0.001), early apoptotic (7.7 ± 1.7%, A+/PI-) (*p* \< 0.01), late apoptotic (21.0 ± 9.0%, A+/PI+) (*p* \< 0.001) and necrotic (10.2 ± 2.0%, A-/PI+) (*p* \< 0.001) cells. When the cells were pretreated with NAC and followed by treatment with 4-NRC, this ROS scavenger partially blocked cell apoptosis, and reached the following values: viable (74.5 ± 15.3%, A-/PI-) (*p* \< 0.001), early apoptotic (4.0 ± 1.2%, A+/PI-), late apoptotic (12.5 ± 9.2%, A+/PI+) and necrotic (9.0 ± 6.1%, A-/PI+) cells. This finding suggests that 4-NRC exerts its cytotoxic effect though not exclusively through ROS-mediated mechanisms.

![Analysis of phosphatidylserine externalization profile in K562 cells after treatment with 4-NRC. The cells (1 × 10^6^ cells/mL) were treated with 4-NRC (27 μM) for 24 h and analyzed using a flow cytometer. Simultaneously, cell groups were also pretreated with N-acetyl-[l]{.smallcaps}-cysteine (NAC) antioxidant agent (2 mM) for 1 h following treatment with 4-NRC to evaluate the involvement of ROS in apoptosis induction. Representative distribution (A) and percentage (B) of necrotic cells in the upper-left quadrant (A-/PI+); early apoptotic cells in the lower-right quadrant (A+/PI-); late apoptotic cells in the upper-right quadrant (A+/PI+); and viable cells in the lower-left quadrant (A-/PI-) in control and 4-NRC groups. Each bar presents mean ± SD of three independent experiments (\*\**p* \< 0.01 and \*\*\**p* \< 0.001 vs. control).](IPHB_A_1311351_F0003_B){#F0003}

In terms of cell cycle progression, 4-NRC significantly arrested the cells at the G0/G1 phase (59.6 ± 1.5%) (*p* \< 0.001). Consequently, we detected significant reductions of 23.35 ± 0.65 and 8.45 ± 0.05% in both the S and G2/M phases (*p* \< 0.001), respectively. In addition, 4-NRC promoted a significant increase in sub-diploid DNA, a characteristic of apoptotic cells, that accumulated in the sub-G1 position of the cell cycle (*p* \< 0.05), in contrast to untreated cells ([Figure 4(A,B)](#F0004){ref-type="fig"}).

![Effects of 4-NRC on the cell cycle and cyclin D1 expression in K562 cells. (A) Representative histograms of the analysis of cell cycle in K562 cells following 24 h treatment with 4-NRC (27 μM). (B) Effects of 4-NRC on cell cycle progression, presented as the percentage of cells in the sub G1, G1, S and G2 phases. Flow cytometry (C) and western blot (D and E) cyclin D1 expression analysis in K562 following treatment with 4-NRC (27 μM) for 24 h. Values represent the means ± SD of two or three independent experiments (\**p* \< 0.05 and \*\**p* \< 0.001 vs. control).](IPHB_A_1311351_F0004_B){#F0004}

As 4-NRC promoted changes in the cell cycle of K562 cells, we investigated the effects of this drug on cyclin D1 expression, a regulator of the G0/G1 phase. Flow cytometric analysis of cells treated with 4-NRC showed a cyclin D1 expression of 65.6 ± 3.1%, a significant decrease when compared to the control (*p* \< 0.05) ([Figure 4(C)](#F0004){ref-type="fig"}). In addition, western blot analysis also revealed a significant reduction in cyclin D1 (*p* \< 0.001) ([Figure 4(D,E)](#F0004){ref-type="fig"}).

Considering that alterations in mitochondrial function are among the early events in apoptosis, the effects in the Δψ~m~ were investigated. The rhodamine 123 staining decreased by 77.2 ± 6.3% (*p* \< 0.001), which suggests the mitochondrial depolarizing ability of 4-NRC ([Figure 5(A)](#F0005){ref-type="fig"}). To confirm this result, Δψ~m~ changes were also analyzed by using a mitochondria fluorescent JC-1 dye. We verified that 4-NRC significantly promoted a reduction in viable cells with mitochondria-aggregated JC-1 (normal Δψ~m~) to 75.6 ± 2.9% with a consequent increase in apoptotic cells showing monomeric and cytosolic JC-1 to 27 ± 3.3% (*p* \< 0.001), when compared to the control (90 ± 4.7 and 10.6 ± 5.3%, respectively) ([Figure 5(B)](#F0005){ref-type="fig"}). The ratios of red (JC-1 aggregates) to green (JC-1 monomers) fluorescence for control and 4-NRC groups were 8.5 and 2.8, respectively, showing that cell apoptosis accompanied the Δψ~m~ changes. Moreover, 4-NRC also led to a significant reduction in mitochondrial activity (*p* \< 0.001) due to a decrease of 59.6 ± 6.9% in the MitoTracker Red staining in relation to untreated cells ([Figure 5(C)](#F0005){ref-type="fig"}). Since 4-NRC promoted mitochondrial membrane depolarization, we verified a significant accumulation of cytosolic cytochrome c in treated cells, in contrast to the control ([Figure 5(D)](#F0005){ref-type="fig"}). These findings demonstrated that a mitochondria-dependent pathway could contribute to 4-NRC-induced apoptosis in K562 cells.

![Effects of 4-NRC on mitochondrial function and ROS production in K562 cells. Cells (1 × 10^6^ cells/mL) were treated with 4-NRC (27 μM) for 24 h and mitochondrial function was analyzed by different assays as follows: (A) 4-NRC-induced Δψ~m~ changes were previously evaluated by rhodamine 123 staining; (B) mitochondrial depolarizing ability of 4-NRC was confirmed by JC-1 staining: representative histogram shows viable cells with mitochondria-aggregated JC-1 (normal Δψ~m~) and apoptotic cells with monomeric and cytosolic JC-1 of control and 4-NRC groups; (C) reduction of mitochondrial mass promoted by 4-NRC was evaluated by Mitotracker Red staining; and (D) cytochrome c release by mitochondria of untreated cells and cells treated with 4-NRC was determined by microscopy: the nuclei were visualized by Hoechst staining and merging the cytochrome c and nuclei representative images were carried out (630 × magnification). Dotted circle represents cytochrome c not detectable in control cells. Scale bars =25 μm. (E) Intracellular ROS generation analysis in K562 cells treated with 4-NRC using a fluorimetric probe, 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA). Results represent the mean ± SD. Data are representative of three independent experiments (\*\**p* \< 0.001 and \*\*\**p* \< 0.0001 vs. control).](IPHB_A_1311351_F0005_C){#F0005}

In parallel, the ROS generation increased in a time-dependent manner after treatment of K562 cells with 4-NRC ([Figure 5(E)](#F0005){ref-type="fig"}). This increase was statistically significant (*p* \< 0.0001), when compared to untreated cells.

Moreover, we observed that caspases were activated during the 4-NRC-induced cell death, since this compound promoted a significant increase of 23.3 ± 6.9 (*p* \< 0.01), 27.5 ± 7.3 (*p* \< 0.01) and 25.2 ± 7.8% (*p* \< 0.001) in caspases -3/7, -8 and -9 activities, respectively. Additionally, when the cells were pretreated with NAC, this substance partially interfered in caspase activation. For this cell group, the values found were 17.7 ± 1.6, 19.0 ± 0.9 and 21.1 ± 2.1% for caspases -3/7, -8 and -9 (*p* \< 0.01), respectively ([Figure 6](#F0006){ref-type="fig"}).

![Analysis of the activation of caspases-3/7, -8 and -9 during 4-NRC-induced apoptosis. The cells (1 × 10^6^ cells/mL) were treated with 4-NRC (27 μM) for 24 h and analyzed using a flow cytometer. To evaluate the involvement of ROS in caspase activation, cell groups were also pretreated with N-acetyl-[l]{.smallcaps}-cysteine (NAC) (2 mM) for 1 h following treatment with 4-NRC. Each bar presents mean ± SD of three independent experiments (\*\**p* \< 0.01 and \*\*\**p* \< 0.001 vs. control).](IPHB_A_1311351_F0006_B){#F0006}

![Multi-target mechanism proposed for 4-NRC-induced apoptosis in multidrug-resistant K562 cells. 4-NRC promotes mitochondrial dysfunction by reduction of mitochondrial activity through loss of Δψ~m~ and pore formation in the membrane of the mitochondria. Thus, it culminates with an increase of ROS production and cytochrome c release from mitochondria to cytosol and consequent caspase activation to trigger cell apoptosis. In parallel, 4-NRC induces cell cycle arrest at G1/G0 stage due to reduced activity of cyclin D1.](IPHB_A_1311351_F0007_B){#F0007}

Discussion {#s0020}
==========

Studies have showed cytotoxic effects of 4-NRC against melanoma solid tumour cell lines, which suggests an apoptotic mechanism (Brohem et al. [@CIT0009], [@CIT0010]). In view of that, the present study clarifies that 4-NRC also promotes interesting cytotoxic activity in p53-null K562 leukemic cells. Morphological analysis of K562 cells after treatment with 4-NRC suggested apoptotic characteristics such as cell shrinkage, nuclear condensation and DNA fragmentation. The pattern of apoptotic cell death was also supported by increased sub-G1, cell cycle arrest at the G1/G0 stage and analysis of phosphatidylserine externalization profile.

DNA fragmentation is a major hallmark of apoptosis and promotes an immediate and p53-independent G1 arrest, due to proteolysis of cyclin D1 (Agami & Bernards [@CIT0002]; Henry et al. [@CIT0023]). During malignant cell transformation, cyclin D1 can perform multiple functions by enhancing several processes through the regulation of pathways related to abnormal cell growth, angiogenesis, resistance to apoptosis and, in addition, it is actively involved in mitochondrial regulation (Tashiro et al. [@CIT0052]; Pestell [@CIT0038]; Alexandrou & Li [@CIT0003]). Since our data suggested an apoptotic process and cell cycle arrest at the G0/G1 stage triggered by 4-NRC, cyclin D1 expression was evaluated. In fact, reduction in cyclin D1 activity was observed after K562 treatment with 4-NRC which suggests a p53-independent G1 arrest.

The mechanisms of apoptosis are highly complex and sophisticated, involving an energy-dependent cascade of molecular events (Elmore [@CIT0017]). It has been shown that PS exposure in response to apoptotic stimuli is an evolutionarily conserved event among cells, and is dependent on caspase activity (Henry et al. [@CIT0023]). From a biochemical standpoint, apoptosis is defined as a caspase-dependent variant of regulated cellular death (Galluzzi et al. [@CIT0020]). Thus, to further determine the apoptotic mechanism triggered by 4-NRC, cytochrome c release, PS exposure, cell cycle analysis, cyclin D1, Δψm, mitochondrial activity, ROS production and caspase activities were evaluated.

The mitochondria could represent a interesting prospective target for chemotherapy-induced apoptosis (Mow et al. [@CIT0036]; Park et al. [@CIT0037]; Lamb et al. [@CIT0028], [@CIT0029]), since the disruption of Δψ~m~ can promote ROS overproduction, leading to cell death (Tait & Green [@CIT0051]; Madamba et al. [@CIT0031]). It has been suggested that cancer cell mitochondria protect tumour cells from death through the down regulation of mitochondrial depolarization inducers (i.e. ROS), changing of chaperones expression involved in the mitochondrial permeability transition pore opening and activation of kinase signalling pathways (Bonora & Pinton [@CIT0008]; Rasola & Bernardi [@CIT0040]). Our data suggest that 4-NRC could interfere with these pathways of resistance to cell death since 4-NRC-induced apoptosis in K562 cells involved a reduction in mitochondrial activity through depolarization and pore formation in the mitochondrial membrane. In addition, this study shows that the pretreatment of K562 cells with NAC followed by treatment with 4-NRC partially blocked cell apoptosis, which suggests that 4-NRC-induced cell death would not seem to be exclusively via ROS-mediated pathways. Similarly, several plant-derived compounds, such as alkaloid berberine (Wang et al. [@CIT0057]), polyphenols silibinin (Jiang et al. [@CIT0025]) and curcumin (Zhang et al. [@CIT0059]), have shown anticancer potential through mitochondrial mechanisms whether associated or otherwise to oxidative stress.

The release of cytochrome c from mitochondria to the cell cytoplasm, due to disruption of Δψ~m~, triggers the activation of the caspase cascade (Stennicke & Salvesen [@CIT0050]; Chen & Wang [@CIT0012]; Abondanza et al. [@CIT0001]), as observed here. In mechanistic terms, this protein causes the activation of apoptosis intrinsic pathway via caspase-9, which further activates caspase-3, thereby establishing the apoptotic process (Galluzzi et al. [@CIT0020]). In parallel, the extrinsic pathway can be triggered by intrinsic pathway via caspase-8 activation (Billen et al., [@CIT0007]; Tait & Green [@CIT0051]). The multi-target action of new drugs has been highlighted as a promising advantage considering cancer cell resistance to conventional therapy (Winter et al. [@CIT0058]). In this respect, we showed that 4-NRC activated both extrinsic and intrinsic apoptotic pathways.

Furthermore, intensive research into small molecules that target cell cycle regulatory proteins has led to the identification of many candidate inhibitors capable of arresting proliferation and inducing apoptosis in neoplastic cells (Lapenna & Giordano [@CIT0030]). Brohem et al. ([@CIT0009]) demonstrated that 4-NRC caused G1 growth arrest in SK-Mel-147 and HNF cells, in contrast to other melanoma cell lines studied which did not present any modulation in cell cycle progression. Here, we clearly demonstrated that 4-NRC arrested K562 cells at the G0/G1 phase in the cell cycle progression, parallel to decreased cyclin D1 expression and reduced mitocondrial activity. Each stage of the cell cycle is regulated by cyclin-dependent protein kinases (CDKs) activated at specific points of the cell cycle (Vermeulen et al. [@CIT0055]; Casimiro et al. [@CIT0011]). In the case of cyclin D1, it forms a holoenzyme with some subsets of CDKs and exerts influence on the cell cycle progression to provide proliferative signals at the G1 phase (Casimiro et al. [@CIT0011]). Its overexpression occurs in multiple cancer types, including chronic myelogenous leukaemia (Groot et al. [@CIT0021]; Casimiro et al. [@CIT0011]), which shows it is a considerable therapeutic target in oncology.

Inhibitors of protein kinases as anticancer drugs have been invigorated by the successful approval of a number of molecules that target tyrosine kinases, such as imatinib, a BCR-ABL protein kinase inhibitor, used for the treatment of CML (Lapenna & Giordano [@CIT0030]). Currently, several drugs targeting the cell cycle, such as flavopiridol, indisulam, AZD5438, SNS-032, bryostatin-1, seliciclib, PD 0332991 and SCH 727965 have entered clinical trials. Clinical studies have demonstrated that CDK inhibitors can be administered to patients with advanced cancer (Dickson & Schwartz [@CIT0016]). The semi-synthetic flavonoid flavopiridol for the treatment of leukaemia has marked antineoplastic properties through inhibition of CDKs (Smolej [@CIT0049]). Moreover, it was found that flavopiridol synergizes with chemotherapy in a sequence-dependent manner (Robak et al. [@CIT0042]).

Although there has been great progress in anticancer therapy, most drugs are nonselective in their mechanism of action and can affect all types of proliferating cells (Krishna et al. [@CIT0027]). 4-NRC also seems to have a nonselective profile since it showed cytotoxicity to normal human lymphocytes. As an alternative, we have proposed liposomes containing 4-NRC as a promising biocompatible and stable drug delivery system (Gaeti et al. [@CIT0019]).

In conclusion, this study demonstrates that 4-NRC has antileukemic properties, inducing apoptosis via mitochondrial-dependent pathways that involve the inhibition of cyclin D1 and consequent G0/G1 cell cycle arrest ([Figure 7](#F0007){ref-type="fig"}). Given that emerging treatment concepts include novel combinations of well-known agents, 4-NRC could be a promising alternative to chemotherapeutic combinations to maximize tumour suppression.
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